Bristol-Myers, AstraZeneca Team Up On $7B Amylin Deal

By Jake Simpson
July 2, 2012, 5:02 PM EDT

U.S. pharmaceutical giant Bristol-Myers Squibb Co. has teamed up with U.K. life sciences company AstraZeneca PLC to acquire diabetes drugmaker Amylin Pharmaceuticals Inc. for roughly $7 billion, the companies announced Friday....

Already a subscriber? Click here to view full article